IRIS
MENNINI, FRANCESCO SAVERIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.258
EU - Europa 2.914
AS - Asia 627
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 5
AF - Africa 4
Totale 29.830
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.215
IT - Italia 1.252
IE - Irlanda 464
UA - Ucraina 307
DE - Germania 304
CN - Cina 296
GB - Regno Unito 141
SE - Svezia 128
FR - Francia 103
VN - Vietnam 96
KR - Corea 91
FI - Finlandia 60
CA - Canada 36
IR - Iran 29
IN - India 28
RU - Federazione Russa 27
BE - Belgio 23
CH - Svizzera 23
PL - Polonia 22
NL - Olanda 19
HK - Hong Kong 15
TW - Taiwan 14
ES - Italia 10
PK - Pakistan 10
SG - Singapore 10
EU - Europa 9
JP - Giappone 9
PT - Portogallo 8
BR - Brasile 6
IQ - Iraq 5
AT - Austria 4
AU - Australia 4
MY - Malesia 4
PH - Filippine 4
RO - Romania 4
BD - Bangladesh 3
CO - Colombia 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
DM - Dominica 3
AE - Emirati Arabi Uniti 2
CL - Cile 2
HT - Haiti 2
HU - Ungheria 2
ID - Indonesia 2
MK - Macedonia 2
TH - Thailandia 2
TR - Turchia 2
AR - Argentina 1
BO - Bolivia 1
CU - Cuba 1
GH - Ghana 1
GR - Grecia 1
HR - Croazia 1
JO - Giordania 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MU - Mauritius 1
MX - Messico 1
NA - Namibia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SI - Slovenia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 29.830
Salva come PNG Salva come JPEG
Città #
Wilmington 7.328
Houston 6.965
Woodbridge 6.868
Fairfield 909
Chandler 510
Ann Arbor 429
Dublin 389
Ashburn 371
Seattle 340
Medford 298
Cambridge 294
Jacksonville 263
Rome 243
New York 210
Dearborn 185
Beijing 159
Lawrence 138
Milan 130
Dong Ket 94
San Diego 85
Menlo Park 59
Phoenix 34
Redwood City 28
Mülheim 26
Seoul 26
Verona 26
Catania 24
London 24
Nanjing 22
Brussels 21
Toronto 19
Norwalk 18
Napoli 17
Florence 16
Turin 16
Hangzhou 15
Kraków 15
Parma 15
Guangzhou 14
Hong Kong 13
Naples 13
Creede 12
Falls Church 12
Zurich 12
Monmouth Junction 11
Ottawa 11
Perugia 11
Taipei 11
University Park 11
Mountain View 10
Kunming 9
Zhengzhou 9
Bangalore 8
Chengdu 8
Dallas 8
Hefei 8
Redmond 8
Saint Petersburg 8
San Francisco 8
San Mateo 8
Tehran 8
Boardman 7
Bologna 7
Genoa 7
Lisbon 7
Miami 7
Palermo 7
Pomezia 7
Rho 7
Amsterdam 6
Brescia 6
Frankfurt am Main 6
Messina 6
Roebling 6
Bari 5
Cattolica 5
Charsadda 5
Duncan 5
Galway 5
Genova 5
Jinan 5
Locate Varesino 5
Los Angeles 5
Padova 5
Scandicci 5
Shanghai 5
Spoltore 5
Trento 5
Washington 5
Andover 4
Catanzaro 4
Ciciliano 4
Fuzhou 4
Goyang-si 4
Helsinki 4
Indiana 4
Islington 4
Leawood 4
Nocera Inferiore 4
Reggio Nell'emilia 4
Totale 27.065
Salva come PNG Salva come JPEG
Nome #
Extending influenza vaccination to individuals aged 50-64: a budget impact analysis 501
Strategie e performance nel mercato farmaceutico italiano: un'analisi empirica 466
General disease costing principles 419
Economic Burden of Human Papillomavirus-Related Diseases in Italy 418
A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache 417
Economic effects of treatment of chronic kidney disease with low-protein diet 411
Health Utilities Lost and Risk Factors Associated With HPV-induced Diseases in Men and Women: The HPV Italian Collaborative Study Group 408
Governance of preventive health intervention and on time verification of its efficiency: the GIOVE study 402
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. 394
Rapporto CEIS-Sanità 2006: il governo del sistema sanitario: complessità e prospettive dei nuovi assetti istituzionali 393
Scenari e strategie nel settore farmaceutico 393
A one-year prospective costing study of botulinum toxin type A treatment of chronic tension headache 382
Cost-effectiveness analysis for the treatment of chronic kidney disease with low-protein diet 382
The perception of corruption in health: AutoCM methods for an international comparison 380
Rapid responses to: Letter to the Editor, by L. Garattini and G. Casadei [Vaccine 27 (38) (20 August 2009) 5171] 379
The new perspectives of italian national health service 375
Towards the eradication of HPV infection through universal specific vaccination 374
A One-Year Economic Evaluation of Botulinum Toxin Type A Treatment of Chronic Tension-type Headaches: Part II 373
Hospital costs incurred by the Italian national health service for invasive cervical cancer 373
Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory 371
Health and economic impact associated with a quadrivalent HPV vaccine in Italy 368
Improving care through health economics analyses: cost of illness and headache 363
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 362
Oral vs injection therapy in the treatment of metastatic colorectal cancer. a cost minimization analysis in a public hospital of the lazio region [Terapia orale vs terapia infusionale nel trattamento del cancro del colon retto localmente avanzato o avanzato analisi di minimizzazione dei costi presso una struttura ospedaliera della regione lazio] 362
Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study 359
Rapporto CEIS-Sanità 2005: sette parole chiave del SSN 357
Pilot evaluation of indirect costs and the impact of bipolar disorder type I 354
Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline 352
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional healthcare providers 351
Rapporto CEIS-Sanità 2004: sostenibilità, equità e ricerca dell'efficienza 347
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy 346
Rapporto CEIS-Sanità 2003: bisogni, risorse e nuove strategie 344
Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: the PATER study 340
Cost of poor adherence to anti-hypertensive therapy in five European countries 340
Public health value of universal HPV vaccination 333
The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. 329
Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis 326
Economic evaluation of spondyloarthritis: Economic impact of diagnostic delay in Italy 324
The economic burden of musculoskeletal disorders on the Italian social security pension system estimated by a Monte Carlo simulation 323
Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients 321
Rapporto CEIS-Sanità 2007: responsabilità, autonomia, sussidiarietà, integrazione, valutazione, empowerment: 6 "nuove" parole chiave per il futuro del SSN 319
Improving care through health economics analyses: cost of illness and headache (general disease costing principles) 316
Joint Procurement and the EU perspective. In Law and Economics of Public Procurement reforms 314
Anti-HPV vaccination in Italy: a review of recent economic data for Italy 312
Does regional belonging explain the similarities in the expenditure determinants of Italian healthcare deliveries?: An approach based on Artificial Neural Networks 312
Equità e fairness del servizio sanitario nazionale italiano 311
Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study 311
The Welfare States in a United Europe 309
Il settore industriale sanitario in Italia 308
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study 308
Dinamiche e determinanti del settore farmaceutico in Europa 305
The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports. 301
Criteri per l'allocazione regionale delle risorse per la sanità: riflessioni sul caso italiano 300
Primary Biliary Cholangitis: advances in management and treatment of the disease 295
Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study. [Costi diretti e indiretti associati a malattie allergiche respiratorie in Italia. Uno studio probabilistico di cost of illness] 294
Time trade-off procedure for measuring health utilities loss with human papillomavirus–induced diseases: a multicenter, retrospective, observational pilot study in Italy 290
Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region 289
Health policy model: Long-term Predictive results associated with the management of hepatitis C virus-induced diseases in Italy 279
PDB51. Direct and indirect cost of diabetes in italy: A prevalence probabilistic approach 277
Dimensioni e tendenze del mercato farmaceutico in Italia (1980/1997) 276
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada 274
A novel method to value real options in health care: The case of a multicohort human papillomavirus vaccination strategy 273
Human papillomavirus 9-valent vaccine for cancer prevention: A systematic review of the available evidence 273
Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanerceptt 264
null 263
Fraud and Corruption in Healthcare: Recognizing Such Phenomena to Combat Them. 261
Early treatment in HIV patients: a cost–utility analysis from the Italian perspective 251
Il settore industriale farmaceutico italiano 250
Analisi di impatto di budget di pasireotide in pazienti con Acromegalia nella prospettiva del Servizio Sanitario Nazionale 248
Introduzione 247
Economics of Headache 244
Strategie e performance delle grandi aziende farmaceutiche in Italia (1979-2001) 237
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 228
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy 223
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 211
The economic impact of biosimilars in Italy: a scenario analysis 204
Erratum to: Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory 202
Economic burden of HPV9-related diseases: a real-world cost analysis from Italy 198
Screening strategies for Hepatitis C Virus elimination in Italy 197
Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. Human menopausal gonadotropin for women undergoing IVF 194
Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma 191
Using real-world data to estimate the Social Security Costs of Retinal Diseases: Results from the Observatory on Legal Blindness 186
Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer 183
Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy 173
Budget Impact Analysis della gestione dell'agitazione psicomotoria con loxapina inalatoria in Italia. 171
HPV Vaccination Concepts in the Reality of Today 171
Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of 3 European Countries 158
Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group 148
Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy 147
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 142
Analisi di Budget Impact su modelli di acquisto e gestione degli ausili per l’incontinenza urinaria a confronto 141
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries 137
Economic Consequences of Anti-HCV Antiviral Treatment Investment from the NHS Perspective 134
PIN79 - ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE: A REAL-WORLD-BASED ANALYSIS FROM PITER DATA 133
. The burden of atopic dermatitis in adults in Italy 130
Estimation of the number of HCV-positive patients in Italy 130
Burden economico della neuropatia ottica ereditaria di Leber (LHON) in Italia: stima dei costi indiretti e diretti a carico del paziente. 107
Invecchiamento della popolazione e sostenibilità del SSN:il ruolo della Health Technology Assessment (HTA) per la valutazione tecnica, economica ed organizzativa della Sanità del futuro 100
The burden of atopic dermatitis in adults in Italy 99
Osteoporosis: Economic Burden of Disease in Italy 95
Totale 28.556
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.272
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.272
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192.049 0 0 0 0 0 0 0 0 0 657 759 633
2019/20208.735 723 592 769 837 795 887 750 736 860 686 573 527
2020/20215.494 521 537 631 569 760 621 640 500 147 145 241 182
2021/20221.610 77 131 140 88 71 88 149 143 95 84 149 395
2022/20231.734 178 113 51 201 154 407 165 109 148 33 120 55
2023/2024774 89 44 69 33 80 233 66 50 63 47 0 0
Totale 30.269